Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $51.45

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $45.09.

A number of research firms have weighed in on ANAB. Guggenheim decreased their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Wedbush reissued an “outperform” rating and set a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday. JPMorgan Chase & Co. cut their target price on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Finally, HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and lowered their price target for the company from $52.00 to $19.00 in a research report on Wednesday.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $15.59 on Thursday. The business has a fifty day moving average price of $25.56 and a 200 day moving average price of $29.43. The company has a market cap of $474.40 million, a P/E ratio of -2.56 and a beta of -0.11. AnaptysBio has a one year low of $14.20 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, sell-side analysts predict that AnaptysBio will post -6.02 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In related news, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the sale, the insider now owns 7,020 shares in the company, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. This trade represents a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock valued at $892,936 over the last 90 days. 33.70% of the stock is owned by insiders.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. acquired a new position in shares of AnaptysBio in the third quarter valued at approximately $49,000. nVerses Capital LLC grew its stake in shares of AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares in the last quarter. Headlands Technologies LLC increased its position in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 2,600 shares during the period. Finally, Point72 DIFC Ltd raised its stake in shares of AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.